Richard S. Levy - 07 Nov 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
07 Nov 2024
Net transactions value
-$1,713,200
Form type
4
Filing time
08 Nov 2024, 17:07:14 UTC
Previous filing
05 Nov 2024
Next filing
11 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $36,800 +5,000 +45% $7.36 16,012 07 Nov 2024 Direct
transaction MDGL Common Stock Sale $1,750,000 -5,000 -31% $350.00 11,012 07 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -5,000 -50% $0.000000 5,000 07 Nov 2024 Common Stock 5,000 $7.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023.
F2 The shares underlying this option are fully vested and exercisable.